A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 204 participants.
Also called NCT07930507
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 204 participants
- Sponsor
- Registry
-
NCT07930507
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China, Hong Kong SAR China, Malaysia, South Korea, Thailand, Vietnam
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07930507. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-21 (anticipated); primary completion 2027-10-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Laroprovstat
- Intervention (Drug)
- Rosuvastatin 1
- Intervention (Drug)
- Rosuvastatin 2
- Intervention (Drug)
- FDC laroprovstat/Rosuvastatin 1
- Intervention (Drug)
- FDC laroprovstat/Rosuvastatin 2
- Intervention (Drug)
- Placebo to match rosuvastatin
- Intervention (Drug)
- Placebo to match laroprovstat or FDC laroprovstat/rosuvastatin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07930507- Content hash
e959f03fc40314988a41727dfed6066640ab058a074753a55aba0cb1d5774039